Provectus amends protocol for phase 3 study of PV-10 in treatment of locally advanced cutaneous melanoma
Major amendments to the protocol include the addition of talimogene laherparepvec (Imlygic) as an option for use as comparator. The amended protocol also extends eligibility to include Stage
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.